Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (600332.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 19.41

From 52W high−26.53%

Volume4.60M

Market capCNY 32.70B

P/E (TTM)11.0x

P/S (TTM)0.4x

Div yield3.84%

Key dataSep 18, 2026

Open

CNY 19.41

From 52W high

−26.53%

Volume

4.60M

Market cap

CNY 32.70B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

8.8x

P/E (TTM)

11.0x

RSI (14)

30.8

MomentumView details →

1D Return

−3.83%

YTD Return

−24.16%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

11.0x

EV/EBITDA

8.8x

EV/Sales

0.5x

P/S (TTM)

0.4x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

16.22%

Net Margin

3.75%

EBITDA Margin

5.55%

ROE (TTM)

7.45%

ROA (TTM)

3.28%

Asset Turnover

0.90x

GrowthView details →

Revenue YoY

+5.29%

EPS YoY

+9.16%

FCF YoY

−87.31%

Revenue CAGR 3Y

+3.13%

EPS CAGR 3Y

−9.06%

EBITDA YoY

—

MomentumView details →

1D Return

−3.83%

YTD Return

−24.16%

1Y Return

−23.57%

RSI (14)

30.8

vs 50D SMA

−7.37%

vs 200D SMA

−15.41%

Capital & dividendView details →

Debt/Equity

0.42x

Current Ratio

1.60x

Quick Ratio

1.29x

Div Yield

3.84%

Div Rate

CNY 0.75

Div Growth 1Y

−6.25%

EarningsView details →

EPS (Actual)

CNY 0.19

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−0.96%

Financials snapshotView financials →

Revenue (TTM)

77.83B

Net Income (TTM)

2.56B

Op. CF (TTM)

2.97B

Next earningsOct 27, 2026 →

Latest newsMore news →

Baiyunshan announced at its 2026 interim results briefing that more than 10 innovative drug pipeline in-licensing projects have completed project initiation, with a pipeline library of over 100 projects and nearly 50 BD innovative drug projects under evaluation.6d ago

Singapore biotech company LionTCR will work with Guangzhou Pharmaceutical Holdings to develop and accelerate the clinical translation of TCR-T cell therapies.25d ago

Similar companies

Zoetis Inc.ZTS ST人福600079.SH 达仁堂600329.SH China Resources Pharmaceutical Group Limited03320.HK China Medical System Holdings Limited00867.HK Haleon plcHLN Find similar companies →

Latest newsMore news →

Baiyunshan announced at its 2026 interim results briefing that more than 10 innovative drug pipeline in-licensing projects have completed project initiation, with a pipeline library of over 100 projects and nearly 50 BD innovative drug projects under evaluation.6d ago Singapore biotech company LionTCR will work with Guangzhou Pharmaceutical Holdings to develop and accelerate the clinical translation of TCR-T cell therapies.25d ago Baiyunshan proposed a cash dividend of 0.30 yuan per share (pre-tax) for the first half of 2026.30d ago